Published in Clin Cancer Res on December 01, 2007
eIF4E phosphorylation promotes tumorigenesis and is associated with prostate cancer progression. Proc Natl Acad Sci U S A (2010) 3.13
Bcl2 family proteins in carcinogenesis and the treatment of cancer. Apoptosis (2009) 1.72
miR-125b promotes growth of prostate cancer xenograft tumor through targeting pro-apoptotic genes. Prostate (2010) 1.55
Regulation of E2Fs and senescence by PML nuclear bodies. Genes Dev (2011) 1.25
Tumor suppressor activity of the ERK/MAPK pathway by promoting selective protein degradation. Genes Dev (2013) 1.18
Estrogen-mediated upregulation of Noxa is associated with cell cycle progression in estrogen receptor-positive breast cancer cells. PLoS One (2011) 0.88
Androgen-regulated expression of arginase 1, arginase 2 and interleukin-8 in human prostate cancer. PLoS One (2010) 0.85
Ebp1 expression in benign and malignant prostate. Cancer Cell Int (2008) 0.84
Immunohistochemical study of PUMA, c-Myb and p53 expression in the benign and malignant lesions of gallbladder and their clinicopathological significances. Int J Clin Oncol (2012) 0.82
Selected markers of proliferation and apoptosis in the parathyroid lesions: a spatial visualization and quantification. J Mol Histol (2008) 0.78
Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med (2011) 27.58
Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med (2012) 20.79
Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med (2012) 15.69
ARID1A mutations in endometriosis-associated ovarian carcinomas. N Engl J Med (2010) 13.07
Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med (2014) 11.05
Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial. Lancet (2011) 8.81
Intermittent androgen suppression for rising PSA level after radiotherapy. N Engl J Med (2012) 8.64
Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. J Natl Cancer Inst (2003) 8.48
Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med (2009) 6.67
Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol (2012) 6.49
Mutation of FOXL2 in granulosa-cell tumors of the ovary. N Engl J Med (2009) 5.63
A nomogram predicting 10-year life expectancy in candidates for radical prostatectomy or radiotherapy for prostate cancer. J Clin Oncol (2007) 4.37
Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials. Eur J Cancer (2012) 4.29
Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trial. Lancet Oncol (2013) 3.38
Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. J Clin Oncol (2005) 3.31
Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer. J Clin Oncol (2005) 3.22
Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202 (alliance). J Clin Oncol (2014) 3.16
A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer. Cancer (2007) 3.15
eIF4E phosphorylation promotes tumorigenesis and is associated with prostate cancer progression. Proc Natl Acad Sci U S A (2010) 3.13
Use of immunohistochemical markers can refine prognosis in triple negative breast cancer. BMC Cancer (2007) 3.09
Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. J Natl Cancer Inst (2005) 3.08
The rate of secondary malignancies after radical prostatectomy versus external beam radiation therapy for localized prostate cancer: a population-based study on 17,845 patients. Int J Radiat Oncol Biol Phys (2010) 3.06
Phase 3, randomized, controlled trial of atrasentan in patients with nonmetastatic, hormone-refractory prostate cancer. Cancer (2008) 2.86
Effects of denosumab on bone mineral density in men receiving androgen deprivation therapy for prostate cancer. J Urol (2009) 2.83
Castration-resistant prostate cancer: from new pathophysiology to new treatment targets. Eur Urol (2009) 2.72
Correlation of proton MR spectroscopic imaging with gleason score based on step-section pathologic analysis after radical prostatectomy. Radiology (2005) 2.71
Subtype-specific mutation of PPP2R1A in endometrial and ovarian carcinomas. J Pathol (2011) 2.64
Management of prostate cancer in older men: recommendations of a working group of the International Society of Geriatric Oncology. BJU Int (2010) 2.59
Denosumab and bone metastasis-free survival in men with nonmetastatic castration-resistant prostate cancer: exploratory analyses by baseline prostate-specific antigen doubling time. J Clin Oncol (2013) 2.52
Estrogen receptor status in BRCA1- and BRCA2-related breast cancer: the influence of age, grade, and histological type. Clin Cancer Res (2004) 2.51
Surveillance guidelines based on recurrence patterns after radical cystectomy for bladder cancer: the Canadian Bladder Cancer Network experience. BJU Int (2012) 2.47
The prognostic implication of the basal-like (cyclin E high/p27 low/p53+/glomeruloid-microvascular-proliferation+) phenotype of BRCA1-related breast cancer. Cancer Res (2004) 2.38
New therapies for castration-resistant prostate cancer: efficacy and safety. Eur Urol (2011) 2.21
PTEN genomic deletion is associated with p-Akt and AR signalling in poorer outcome, hormone refractory prostate cancer. J Pathol (2009) 2.13
A combined analysis of outcome following breast cancer: differences in survival based on BRCA1/BRCA2 mutation status and administration of adjuvant treatment. Breast Cancer Res (2003) 2.09
Characterization of the molecular differences between ovarian endometrioid carcinoma and ovarian serous carcinoma. J Pathol (2010) 2.04
High provider volume is associated with lower rate of secondary therapies after definitive radiotherapy for localized prostate cancer. Eur Urol (2007) 2.02
Multicenter phase II study of combined neoadjuvant docetaxel and hormone therapy before radical prostatectomy for patients with high risk localized prostate cancer. J Urol (2008) 1.95
Tumour necrosis is an indicator of aggressive biology in patients with urothelial carcinoma of the upper urinary tract. Eur Urol (2009) 1.92
uPM3, a new molecular urine test for the detection of prostate cancer. Urology (2004) 1.91
Up-regulation of Wnt-1 and beta-catenin production in patients with advanced metastatic prostate carcinoma: potential pathogenetic and prognostic implications. Cancer (2004) 1.90
Improved prediction of disease relapse after radical prostatectomy through a panel of preoperative blood-based biomarkers. Clin Cancer Res (2008) 1.90
Nomogram predicting the probability of early recurrence after radical prostatectomy for prostate cancer. J Urol (2008) 1.86
Cost-effectiveness of zoledronic acid for the prevention of skeletal complications in patients with prostate cancer. J Urol (2004) 1.85
Genomic deletion of PTEN is associated with tumor progression and early PSA recurrence in ERG fusion-positive and fusion-negative prostate cancer. Am J Pathol (2012) 1.80
Randomized phase II study of docetaxel and prednisone with or without OGX-011 in patients with metastatic castration-resistant prostate cancer. J Clin Oncol (2010) 1.76
High radical prostatectomy surgical volume is related to lower radical prostatectomy total hospital charges. Eur Urol (2006) 1.76
Expression of RANKL/RANK/OPG in primary and metastatic human prostate cancer as markers of disease stage and functional regulation. Cancer (2006) 1.75
Clinicians are poor raters of life-expectancy before radical prostatectomy or definitive radiotherapy for localized prostate cancer. BJU Int (2007) 1.68
KIF1A, an axonal transporter of synaptic vesicles, is mutated in hereditary sensory and autonomic neuropathy type 2. Am J Hum Genet (2011) 1.66
Markers of bone metabolism and survival in men with hormone-refractory metastatic prostate cancer. Clin Cancer Res (2006) 1.65
Plasmacytoid urothelial carcinoma, a chemosensitive cancer with poor prognosis, and peritoneal carcinomatosis. J Urol (2012) 1.65
The aging male population and medical care for benign prostatic hyperplasia in Canada. Can Urol Assoc J (2010) 1.63
Partial cystectomy does not undermine cancer control in appropriately selected patients with urothelial carcinoma of the bladder: a population-based matched analysist. Urology (2009) 1.58
The contemporary role of lymph node dissection during nephroureterectomy in the management of upper urinary tract urothelial carcinoma: the Canadian experience. Urology (2012) 1.57
Molecular description of a 3D in vitro model for the study of epithelial ovarian cancer (EOC). Mol Carcinog (2007) 1.55
Chromosome 3 anomalies investigated by genome wide SNP analysis of benign, low malignant potential and low grade ovarian serous tumours. PLoS One (2011) 1.53
Impact of hemochromatosis gene (HFE) mutations on epithelial ovarian cancer risk and prognosis. Int J Cancer (2011) 1.52
Poor overall survival in septa- and octogenarian patients after radical prostatectomy and radiotherapy for prostate cancer: a population-based study of 6183 men. Eur Urol (2007) 1.51
Placental cadherin and the basal epithelial phenotype of BRCA1-related breast cancer. Clin Cancer Res (2005) 1.51
Survival after radical prostatectomy and radiotherapy for prostate cancer: a population-based study. Can Urol Assoc J (2009) 1.51
Radical versus partial nephrectomy: effect on overall and noncancer mortality. Cancer (2009) 1.51
Characterization of the intra-prostatic immune cell infiltration in androgen-deprived prostate cancer patients. J Immunol Methods (2009) 1.48
Prostate-specific antigen improves the ability of clinical stage and biopsy Gleason sum to predict the pathologic stage at radical prostatectomy in the new millennium. Eur Urol (2007) 1.45
TMPRSS2-ERG status is not prognostic following prostate cancer radiotherapy: implications for fusion status and DSB repair. Clin Cancer Res (2013) 1.45
Characterization of ovarian cancer ascites on cell invasion, proliferation, spheroid formation, and gene expression in an in vitro model of epithelial ovarian cancer. Neoplasia (2007) 1.45
Prediction of pathological stage is inaccurate in men with PSA values above 20 ng/mL. Eur Urol (2006) 1.42
Absence of prognostic value of nuclear shape factor analysis in colorectal carcinoma: relevance of interobserver and intraobserver variability. Dis Colon Rectum (2008) 1.41
A framework for biobank sustainability. Biopreserv Biobank (2014) 1.41
Nuclear factor-kappaB nuclear localization is predictive of biochemical recurrence in patients with positive margin prostate cancer. Clin Cancer Res (2004) 1.40
Randomized, placebo-controlled, phase III trial of sunitinib plus prednisone versus prednisone alone in progressive, metastatic, castration-resistant prostate cancer. J Clin Oncol (2013) 1.38
Disruption of the expected positive correlation between breast tumor size and lymph node status in BRCA1-related breast carcinoma. Cancer (2003) 1.38
Expression and nuclear localization of ErbB3 in prostate cancer. Clin Cancer Res (2006) 1.36
A population based assessment of perioperative mortality after cystectomy for bladder cancer. J Urol (2009) 1.35
Background for the proposal of SIOG guidelines for the management of prostate cancer in senior adults. Crit Rev Oncol Hematol (2010) 1.34
Transition zone prostate cancer: metabolic characteristics at 1H MR spectroscopic imaging--initial results. Radiology (2003) 1.33
Nuclear localization of nuclear factor-kappaB p65 in primary prostate tumors is highly predictive of pelvic lymph node metastases. Clin Cancer Res (2006) 1.30
Management of skeletal-related events in patients with advanced prostate cancer and bone metastases: Incorporating new agents into clinical practice. Can Urol Assoc J (2012) 1.27
Tissue array analysis of expression microarray candidates identifies markers associated with tumor grade and outcome in serous epithelial ovarian cancer. Int J Cancer (2006) 1.27
Impact of germline BRCA1 mutations and overexpression of p53 on prognosis and response to treatment following breast carcinoma: 10-year follow up data. Cancer (2003) 1.27
Regulation of E2Fs and senescence by PML nuclear bodies. Genes Dev (2011) 1.25
External validation of a biomarker-based preoperative nomogram predicts biochemical recurrence after radical prostatectomy. J Clin Oncol (2008) 1.18
Tumor suppressor activity of the ERK/MAPK pathway by promoting selective protein degradation. Genes Dev (2013) 1.18
Expression of NF-kappaB in prostate cancer lymph node metastases. Prostate (2004) 1.18
Accuracy of life tables in predicting overall survival in patients after radical prostatectomy. BJU Int (2008) 1.18
Fascin regulates prostate cancer cell invasion and is associated with metastasis and biochemical failure in prostate cancer. Clin Cancer Res (2009) 1.17
Modeling a lethal prostate cancer variant with small-cell carcinoma features. Clin Cancer Res (2011) 1.15
Effects of skeletal morbidities on longitudinal patient-reported outcomes and survival in patients with metastatic prostate cancer. Support Care Cancer (2007) 1.14